Skip to main content

Table 1 Sociodemographic and clinical characteristics of study participants

From: Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease

Variables n = 160
Age (years) – mean ± SD 54.0 ± 11.2
Gender – n (%)
 Female 80 (50.0)
 Male 80 (50.0)
Race self-declaration – n (%)
 White 99 (61.9)
 Black 14 (8.8)
 Mulatto 37 (23.1)
 Other 10 (6.2)
Educational level – n (%)
 Elementary school incomplete 52 (32.5)
 Elementary school complete 26 (16.3)
 Secondary school 56 (35.1)
 College 21 (13.2)
 Postgraduate 5 (3.1)
Current employment status – n (%)
 Active 66 (41.3)
 Away due to PsA 33 (20.6)
 Retired due to PsA 20 (12.5)
 Retired or away for other reasons 31 (19.4)
 Unemployed 10 (6.3)
Classification of BMI – n (%)
 Eutrophic 35 (21.9)
 Overweight 70 (43.8)
 Obesity 55 (34.4)
Smoker – n (%) 24 (15.0)
Alcoholic – n (%) 19 (11.9)
Metabolic syndrome 100 (62.5)
Comorbidities
 Systemic Arterial Hypertension 82 (51.3)
 Diabetes Mellitus 34 (21.3)
 Dyslipidemia 106 (66.3)
 Depressive Disorder 31 (19.4)
 Fibromyalgia 28 (17.5)
Duration of cutaneous disease/psoriasis (years) - median (P25-P75) 18 (8-27)
Time of PsA symptoms (years) - median (P25-P75) 8 (5-14)
Type of psoriasis – n (%)
 Plaque 142 (88,8)
 Palm plantar 10(6,3)
 Others 8(5,1)
Onicopathy – n (%) 54 (33,8)
Current treatment – n (%)
 Biological 107 (66,9)
Joint count with edema - median (P25-P75) 1 (0-3)
Counting of joints with painful - median (P25-P75) 2 (0-5)
Enthesitis (SPARCC ≥1) – n (%) 33 (20.6)
Radiographic changed – n (%) 115 (71.9)
PASI≤1 – n (%) 66 (41.3)
Type of PsA involvment – n(%)
 Peripheral 109 (68,1)
 Axial 3 (1,9)
 Mixed 48 (30,0)
  1. SPARCC Spondyloarthritis Research Consortium of Canada Enthesitis Index. PASI Psoriasis Area Severity Index